AbbVie (NYSE:ABBV) Stock Price Down 1.6% – What’s Next?

AbbVie Inc. (NYSE:ABBV) shares traded down 1.6% on Tuesday . The company traded as low as $221.91 and last traded at $223.7340. 6,278,799 shares traded hands during trading, a decline of 1% from the average session volume of 6,334,430 shares. The stock had previously closed at $227.45.

Analysts Set New Price Targets

ABBV has been the subject of a number of analyst reports. Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. BMO Capital Markets upped their price objective on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, September 12th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and upped their price target for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Finally, Evercore ISI lifted their price objective on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $244.55.

AbbVie Price Performance

The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The firm has a fifty day simple moving average of $227.20 and a two-hundred day simple moving average of $210.24. The firm has a market cap of $395.43 billion, a PE ratio of 169.50, a PEG ratio of 1.21 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the prior year, the firm earned $3.00 EPS. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is 496.97%.

Institutional Trading of AbbVie

Several hedge funds have recently made changes to their positions in ABBV. Chelsea Counsel Co. bought a new stake in AbbVie during the third quarter worth approximately $26,000. TD Capital Management LLC boosted its holdings in shares of AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares during the period. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie in the 2nd quarter worth approximately $25,000. Texas Capital Bancshares Inc TX bought a new position in shares of AbbVie during the 3rd quarter valued at approximately $31,000. Finally, Evolution Wealth Management Inc. purchased a new stake in AbbVie during the 2nd quarter valued at $26,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.